New drug targets Hard-to-Treat cancers in early trial
NCT ID NCT05485974
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial is testing a new drug called HBI-2438 in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change called KRAS G12C. The main goals are to find the safest dose and understand how the drug moves through the body. About 44 adults who have tried other treatments without success are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HBI-2438 (a KRAS G12C inhibitor)
What this could lead to
If it works, this could point toward a new treatment option for people with certain cancers that have a specific genetic mutation (KRAS G12C).
What could go wrong
This is a very early (Phase 1) trial with only 44 participants, so it is primarily testing safety and dosing. It is too soon to know if the drug will shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alliance for Multispecialty Research, LLC
Kansas City, Missouri, 64114, United States
-
BRCR Medical Center
Plantation, Florida, 33322, United States
-
California Cancer Associates for Research and Excellence, Inc. (cCare)
Encinitas, California, 92024, United States
-
California Cancer Associates for Research and Excellence, Inc. (cCare)
San Marcos, California, 92069, United States
-
Gabrail Cancer Center
Canton, Ohio, 44718, United States
-
Innovative Clinical Research Institute (ICRI)
Whittier, California, 90603, United States
-
Michigan Center of Medical Research
Farmington Hills, Michigan, 48334, United States
-
Pan American Center for Oncology Trials (PanOncology Trials)
Rio Piedras, Puerto Rico, 00935, Puerto Rico
-
Sarcoma Oncology
Santa Monica, California, 90403, United States
-
The Oncology Institute of Hope and Innovation
Glendale, California, 91204, United States
-
The Oncology Institute of Hope and Innovation
Long Beach, California, 90805, United States
-
The Oncology Institute of Hope and Innovation
Pasadena, California, 91105, United States
-
The Oncology Institute of Hope and Innovation
Santa Ana, California, 92705, United States
-
The Oncology Institute of Hope and Innovation
Whittier, California, 90603, United States